## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1. Claim 1 (Currently Amended) A compound comprising having a formula:

or a pharmaceutically acceptable salt or a  $\underline{C_{1:6}}$  alkyl ester prodrug thereof; wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is  $-(CH_2)_{6^-}$ ,  $cis - CH_2CH = CH - (CH_2)_{3^-}$ , or  $-CH_2C = C - (CH_2)_{3^-}$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

X is selected from the group consisting of CO<sub>2</sub>H, CONHR<sub>2</sub>, CONR<sub>2</sub>, CON(OR)R, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>R, SO<sub>2</sub>NR<sub>2</sub>, SO<sub>2</sub>NHR, and

J is C=O, CHOH, or CH<sub>2</sub>CHOH;

R is independently H,  $C_1$ – $C_6$  alkyl, phenyl, or biphenyl; and E is  $C_3$ – $C_6$  alkyl,  $C_4$ – $C_{10}$  cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety—thienyl, furyl, pyridinyl, benzothienyl, or benzofuryl having from 0 to 2 substituents, wherein said substituents are independently selected from: a hydrocarbon moiety having from 1 to 4 carbon

2

atoms, CO<sub>2</sub>H, alkoxy having from 1 to 3 carbon atoms, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, and SO<sub>3</sub>H comprise up to 4 non-hydrogen atoms.

2. Claim 2 (Currently Amended) The compound of claim 1 eomprisinghaving a formula:

or a pharmaceutically acceptable salt or a prodrug thereof.

3. Claim 3 (Currently Amended) The compound of claim 1 eemprisinghaving a formula:

or a pharmaceutically acceptable salt or a prodrug thereof.

- 4. Claim 4 (Original) The compound of claim 3 wherein J is C=O.
- 5. Claim 5 (Original) The compound of claim 3 wherein J is CHOH.
- 6. Claim 6 (Original) The compound of claim 3 wherein X is CO₂H.
- 7. Claim 7 (Currently Amended) The compound of claim 3 wherein E is phenyl, thienyl, furyl, pyridinyl, napthyl, benzothienyl, or benzofuryl having from 0 to 2 substituents comprising up to 4 non-hydrogen atoms.
- 8. Claim 8 (Currently Amended) The compound of claim 3 wherein E is *n*-butyl.
- Claim 9 (Currently Amended) The compound of claim 1 eemprisinghaving a formula:

3

Docket No. 17712 (AP)

or a pharmaceutically acceptable salt or a prodrug thereof.

10. Claim 10 (Currently Amended) The compound of claim 1 eemprisinghaving a formula:

or a pharmaceutically acceptable salt or a prodrug thereof.

11. Claim 11 (Currently Amended) The compound of claim 1 semprisinghaving a formula:

or a pharmaceutically acceptable salt or a prodrug thereof.

12. Claim 12 (Currently Amended) A liquid composition comprising

4

Docket No. 17712 (AP)

or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is —(CH<sub>2</sub>)<sub>5</sub>-, cis –CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or –CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-, wherein 1 or 2 carbon atoms may be substituted with S or O;

X-is selected from the group consisting of CO<sub>2</sub>H, CONHR<sub>2</sub>, CONR<sub>2</sub>, CON(OR)R, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>R, SO<sub>2</sub>NR<sub>2</sub>, SO<sub>2</sub>NH<sub>R</sub>, and



## J is C=O, CHOH, or CH2CHOH;

R is independently H, C<sub>4</sub>-C<sub>6</sub> alkyl, phenyl, or biphenyl; and


E.is C<sub>3</sub>-C<sub>6</sub> alkyl, C<sub>4</sub>-C<sub>10</sub>-cycloalkyl, phenyl or napthyl having from 0 to 2

substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms;

the compound according to claim 1 and a pharmaceutically acceptable excipient, wherein said liquid is formulated for ophthalmic use.

43. Claim 13 (Currently Amended) A method of treating glaucoma or ocular hypertension comprising administering a compound of claim 1 to a mammal, wherein said method is useful for the treatment of glaucoma or ocular hypertension in said mammal, said compound comprising

Docket No. 17712 (AP)



or a pharmaceutically acceptable salt or a prodrug thereof:

wherein a dashed line represents the presence or absence of a double bond or a triple bond:

A is —(CH<sub>2</sub>)<sub>5</sub>-, cis –CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or –CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-, wherein 1 or 2 carbon atoms may be substituted with S or O;

X-is selected from the group consisting of CO<sub>2</sub>H, CONHR<sub>2</sub>, CONR<sub>2</sub>, CON(OR)R, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>R, SO<sub>2</sub>NR<sub>2</sub>, SO<sub>2</sub>NH<sub>R</sub>, and



J is C=O, CHOH, or CH2CHOH;

R is independently H, C<sub>4</sub>-C<sub>6</sub>-alkyl, phenyl, or biphenyl; and E.is-C<sub>5</sub>-C<sub>6</sub>-alkyl, C<sub>4</sub>-C<sub>40</sub>-cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.